PRESS RELEASE

Presentation of New Data for MDxHealth’s Prostate Cancer Diagnostic Tests at AUA 2019 Annual Meeting

*Moderated posters feature clinical validations of SelectMDx and ConfirmMDx*

IRVINE, CA, and HERSTAL, BELGIUM - MAY 3, 2019 - MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that positive data demonstrating the clinical value of ConfirmMDx and SelectMDx for prostate cancer will be presented in two moderated posters at the 2019 American Urological Association (AUA) Annual Meeting, May 1-6 in Chicago.

Data highlights

- Clinical utility study demonstrates that ConfirmMDx had a significant positive impact on repeat prostate biopsy decision-making in a US community urology practice setting.
- In a 1,955-patient clinical validation study, SelectMDx demonstrated a high sensitivity and negative predictive value for the detection of clinically significant prostate cancer.

Details are as follows:

**Poster:** MP24-02: Clinical Utility of ConfirmMDx For Prostate Cancer in a Community Urology Practice  
**Date:** Saturday, May 4, 2019  
**Time:** 07:00 - 09:00 CDT  
The abstract and authors are available to view [here](#).

**Poster:** MP24-04: A 2-Gene MRNA Urine Test For Detection of High-Grade Prostate Cancer Prior to Initial Prostate Biopsy  
**Date:** Saturday, May 4, 2019  
**Time:** 07:00 - 09:00 CDT  
The abstract and authors are available to view [here](#).

The AUA annual meeting takes place at the McCormick Place convention center in Chicago, and more information is available on the meeting [website](#).

**For more information:**

*Consilium Strategic Communications*
Amber Fennell, Chris Welsh, David Daley, Marieke Vermeersch  
UK: +44 20 3709 5701  
mdxhealth@consilium-comms.com
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of therapeutic response. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com.

Disclaimer
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.